RxDoctor Payments Data

David Holman, MD

Family Medicine · Philip, SDNPI 1629048954

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $555 and has fallen 85.8% since, to $79 in 2025.

$1,449in general payments, 2019–2025

Across 95 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$207
  • Johnson & Johnson$181
  • Pfizer$157
  • Lilly USA, LLC$134
  • Novo Nordisk$122
  • E.r. Squibb & Sons, L.L.C.$118
  • plus $529 from 11 others

What the payments were for

  • Food & beverage$1,449100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,449 in reported general payments places this provider in the 85th percentile of 408 family medicine providers in South Dakota.

See all family medicine providers in South Dakota

Medicare billing

Part B allowed, 2024
$11,344
Medicare patients
48
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban255$133,564
JardianceEmpagliflozin53$45,039
OzempicSemaglutide17$24,460
TrulicityDulaglutide15$17,170
XareltoRivaroxaban41$16,951
FarxigaDapagliflozin Propanediol30$15,682
SynthroidLevothyroxine Sodium167$9,713
Potassium Chloride290$7,176
Metoprolol Succinate386$5,915
Fentanyl36$5,339
Breo ElliptaFluticasone/Vilanterol12$5,323
ShingrixVaricella-Zoster Ge/As01b/Pf24$5,241
Tamsulosin Hcl278$5,155
Losartan Potassium465$5,035
Levothyroxine Sodium426$4,795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$157$133,564255 claims
Boehringer IngelheimJardiance$64$45,03953 claims
Novo NordiskOzempic$122$24,46017 claims
Lilly USA, LLCTrulicity$134$17,17015 claims
Johnson & JohnsonXarelto$181$16,95141 claims
AstraZenecaFarxiga$101$15,68230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 408 family medicine providers in South Dakota.

Other family medicine in Philip

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →